Allergy Therapeutics PLC
LSE:AGY
Allergy Therapeutics PLC
LSE:AGY
Price:
2.875 GBX
Market Closed
Updated:
May 4, 2024
Allergy Therapeutics PLC
Cash from Investing Activities
|
Allergy Therapeutics PLC
Cash from Investing Activities Peer Comparison
Comparables:
GSK
AZN
INDV
HIK
DPH
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Cash from Investing Activities
-£3.5m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-10%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cash from Investing Activities
-£1.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
AstraZeneca PLC
LSE:AZN
|
Cash from Investing Activities
-$4.1B
|
CAGR 3-Years
-142%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-3%
|
|
|
Indivior PLC
LSE:INDV
|
Cash from Investing Activities
-$98m
|
CAGR 3-Years
-190%
|
CAGR 5-Years
-90%
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cash from Investing Activities
-$333m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-11%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Cash from Investing Activities
-£426.2m
|
CAGR 3-Years
-74%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-36%
|
See Also
What is Allergy Therapeutics PLC's Cash from Investing Activities?
Cash from Investing Activities
-3.5m
GBP
-3.5m
GBP
Based on the financial report for Dec 31, 2023, Allergy Therapeutics PLC's Cash from Investing Activities amounts to -3.5m GBP.
What is Allergy Therapeutics PLC's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
-10%
-10%
Over the last year, the Cash from Investing Activities growth was 25%. The average annual Cash from Investing Activities growth rates for Allergy Therapeutics PLC have been -16% over the past three years , -9% over the past five years , and -10% over the past ten years .
You don't have any saved screeners yet
